Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

Figure 3

Her2-pDNA vaccination generates Her2-specific humoral immunity. A-B. Mean binding activity derived from A. Her2-specific or B. tetanus toxoid Ig λ-subclass specific ELISAs. Bars show the mean (± s.e.m.) binding activity of patients evaluable at all time points (patient #3, 4, 8, pre, post and late). C. Binding activity in the serum of all patients at all available individual time points (pre- and post-immunization as well as long-term follow up at 22-41 months following the last immunization).

Back to article page